ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
HNRNPC as a candidate biomarker for chemoresistance in gastric cancer.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 71 citations in OpenAlex.
- Multiomics analysis identifies the prognostic significance and biological roles of the HNRNP family in lung adenocarcinoma.Discover oncology · 2026Article
- mFrontiers in cell and developmental biology · 2026Review
- Oncotransformation in Bhas 42 Cell Transformation Assay by Typical Non-Genotoxic Carcinogens, PFOA and PFOS, and Time-Course Transcriptome Analysis.Biomolecules · 2025Article
- Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival.Biological research · 2025Article
- Expression and prognostic significance of the m6A RNA methylation regulator HNRNPC in HNSCC.Frontiers in oncology · 2025Article
- Tumor Microenvironment in Clear Cell Renal Cell Carcinoma: A Comprehensive Analysis.Iranian journal of public health · 2024Article
- Novel Insights into the Links between N6-Methyladenosine and Regulated Cell Death in Musculoskeletal Diseases.Biomolecules · 2024Review
- Hsa_circ_0014606 Derived from Exosomes Promotes Gastric Carcinoma Tumorigenesis and Proliferation by Sponging miR-514b-3p to Upregulate HNRNPC.Digestive diseases and sciences · 2024Article
- Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma.Molecular & cellular oncology · 2024Article
- m6A regulators are differently expressed and correlated with immune response of pancreatic adenocarcinoma.Journal of cancer research and clinical oncology · 2023Article
- N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.Frontiers in endocrinology · 2023Article
- Identification of m6a-related signature genes in esophageal squamous cell carcinoma by machine learning method.Frontiers in genetics · 2023Article
- HNRNPC, a predictor of prognosis and immunotherapy response based on bioinformatics analysis, is related to proliferation and invasion of NSCLC cells.Respiratory research · 2022Article
- Biological and pharmacological roles of mMolecular cancer · 2022Review
- Identification of a five m6A-relevant mRNAs signature and risk score for the prognostication of gastric cancer.Journal of gastrointestinal oncology · 2022Article
- An analysis of the role of HnRNP C dysregulation in cancers.Biomarker research · 2022Review
- Article
- Article
- Identification of HnRNPC as a novel Tau exon 10 splicing factor using RNA antisense purification mass spectrometry.RNA biology · 2022Article
- Landscape of Alternative Splicing Events Related to Prognosis and Immune Infiltration in Glioma: A Data Analysis and Basic Verification.Journal of immunology research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemoresistance is a major cause of treatment failure and high mortality in advanced gastric cancer (AGC). Currently, the mechanism of chemoresistance remains unclear, and there is no biomarker to accurately predict the efficacy of chemotherapy. In the present study, we established human gastric cancer (GC) cell lines resistant to 5-fluorouracil (5FU), paclitaxel (TA), or cisplatin (DDP) by gradient drug treatment and generated a novel monoclonal antibody 5B2 targeting heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) overexpressed in chemoresistant GC cells. Overexpressing HNRNPC in GC cells promoted chemoresistance, and knockdown of HNRNPC by small interfering RNA (siRNA) reversed chemoresistance. By utilizing available datasets, we demonstrated that high level of HNRNPC transcript indicated poor overall survival (OS) and free of progression (FP). HNRNPC expression was negatively correlated with OS of GC patients treated with 5FU-based drugs and with time to progression (TTP) of GC patients treated with CF regimen. These data suggest the potential usefulness of HNRNPC as a prognostic and therapeutic marker of GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.